Secondary stroke prevention through pathway management

SeconDary Stroke PreVEntion ThRough Pathway ManagemenT (DiVERT Stroke Phase II)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN43724416

Enrollment

1500

Registered

2022-10-12

Start date

2023-08-21

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke Circulatory System

Interventions

Current interventions as of 23/08/2023: The DiVERT Stroke II study care pathway will enable physicians to use stroke etiology, presentation characteristics, neuroimaging factors and other clinical r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current inclusion criteria as of 23/08/2023: 1. Patients with a cryptogenic stroke or large artery atherosclerosis or small vessel occlusion hospitalization between 2023 and 2024 2. Age =18 years _____ Previous inclusion criteria: 1. Patients with a cryptogenic stroke or large artery atherosclerosis or small vessel occlusion hospitalization between 2022 and 2024 2. Age =18 years

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 23/08/2023: 1. The following information will be collected within 180 days prior to the index stroke hospitalization from patient records and measured through chart review: 1.1. Medical history 1.2. Alcohol consumption 1.3. CHA2DS2 VASc Score (if congestive heart failure +1, if hypertension +1, if age =75 +2, if diabetes +1, if previous stroke +2, if vascular disease +1, if age 65 to 74 +1, and if sex category (female) +1) (most recent within 180 days prior to index hospitalization, if available) 1.4. Lab Tests: CRP (C-reactive protein), BNP (brain natriuretic peptide) (most recent within 180 days prior to index hospitalization, if available) 2. The following information will be collected during the index stroke hospitalization from patient records: 2.1. Hospitalization Dates measured by admission and discharge dates 2.2. Neurology diagnostic testing measured through chart review 2.3. EP Consultation measured through chart review 2.4. Short-term/external monitors, wearables, and/or ICM recommendation (if applicable/available) measured through DiVERT Stroke Phase II Care Pathway and chart review 2.5. Short-term/external monitors, wearables, and/or ICM use (if applicable/available) measured through DiVERT Stroke Phase II Care Pathway and chart review 3. The following information will be collected at follow-up visits through 180 days post-index stroke hospitalization (i.e., discharge) from patient records and measured through chart review: 3.1. Discharge location (SNF (skilled nursing facility), inpatient, home, etc.) 3.2. Prescribed stroke-related follow-up cadence (office and remote) 3.3. Stroke-related follow-up dates 3.4. Neurology diagnostic testing 4. Economic information to be collected from patient records and measured via claims data and chart review include: 4.1. Total cost of stroke diagnostic work-up for index hospitalization and through 180 days of follow-up 4.2. Total cost of index stroke hospitalization 4.3.	—

Measure

Time frame

Current primary outcome measure as of 23/08/2023: 1. The following information will be collected within 180 days prior to the index stroke hospitalization from patient records and measured through chart review: 1.1. Medical history 1.2. Alcohol consumption 1.3. CHA2DS2 VASc Score (if congestive heart failure +1, if hypertension +1, if age =75 +2, if diabetes +1, if previous stroke +2, if vascular disease +1, if age 65 to 74 +1, and if sex category (female) +1) (most recent within 180 days prior to index hospitalization, if available) 1.4. Lab Tests: CRP (C-reactive protein), BNP (brain natriuretic peptide) (most recent within 180 days prior to index hospitalization, if available) 2. The following information will be collected during the index stroke hospitalization from patient records: 2.1. Hospitalization Dates measured by admission and discharge dates 2.2. Neurology diagnostic testing measured through chart review 2.3. EP Consultation measured through chart review 2.4. Short-term/external monitors, wearables, and/or ICM recommendation (if applicable/available) measured through DiVERT Stroke Phase II Care Pathway and chart review 2.5. Short-term/external monitors, wearables, and/or ICM use (if applicable/available) measured through DiVERT Stroke Phase II Care Pathway and chart review 3. The following information will be collected at follow-up visits through 180 days post-index stroke hospitalization (i.e., discharge) from patient records and measured through chart review: 3.1. Discharge location (SNF (skilled nursing facility), inpatient, home, etc.) 3.2. Prescribed stroke-related follow-up cadence (office and remote) 3.3. Stroke-related follow-up dates 3.4. Neurology diagnostic testing 4. Economic information to be collected from patient records and measured via claims data and chart review include: 4.1. Total cost of stroke diagnostic work-up for index hospitalization and through 180 days of follow-up 4.2. Total cost of index stroke hospitalization 4.3.

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

United States of America

Contacts

Public ContactJessica Mikacevich

jessica.m.mikacevich@medtronic.com+1 651 315 2719

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026